TITLE

Erythropoietin for ribavirin-induced anemia in hepatitis C: more answers but many more questions

AUTHOR(S)
Dev, Anouk; Patel, Keyur; Muir, Andrew; McHutchison, John G.
PUB. DATE
November 2003
SOURCE
American Journal of Gastroenterology;Nov2003, Vol. 98 Issue 11, p2344
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
No abstract available.
ACCESSION #
11469022

 

Related Articles

  • ITPA polymorphisms "strongly" linked to ribavirin-induced anaemia.  // Reactions Weekly;9/4/2010, Issue 1317, p2 

    The article focuses on a study in Japan which affirms the strong link between four polymorphisms located around the inosine triphosphate pyrophosphatase (ITPA) gene and ribavirin-induced anemia in Japanese patients with hepatitis C virus (HCV).

  • Human Recombinant Erythropoietin in the Prevention and Treatment of Anemia of Prematurity. Ohls, R.K. // Pediatric Drugs;2002, Vol. 4 Issue 2, p111 

    Human recombinant erythropoietin has been studied extensively as treatment for a variety of anemias. Since in vitro studies showed the primary etiology of the anemia of prematurity to be insufficient serum erythropoietin concentrations, clinical trials have evaluated the administration of human...

  • Is the anemia of CKD always due to erythropoietin deficiency? Garcia, Jennifer L. // Veterinary Medicine;Aug2011, Vol. 106 Issue 8, p384 

    The article provides an answer to a question on the cause of the anemia of chronic kidney disease (CKD) due to erythropoietin deficiency.

  • ITPA variants protective against ribavirin-induced anaemia.  // Reactions Weekly;7/10/2010, Issue 1309, p6 

    The article discusses a research study which found that variants in the inosine triphosphate pyrophosphatase (ITPA) gene offers protection against ribavirin-induced haemolytic anemia and decreases the need for ribavirin dose reduction in patients with chronic hepatitis C virus.

  • Ribavirin-Induced Anemia in Hepatitis C Virus Patients Undergoing Combination Therapy. Krishnan, Sheeja M.; Dixit, Narendra M. // PLoS Computational Biology;Feb2011, Vol. 7 Issue 2, p1 

    The current standard of care for hepatitis C virus (HCV) infection - combination therapy with pegylated interferon and ribavirin - elicits sustained responses in only ∼50% of the patients treated. No alternatives exist for patients who do not respond to combination therapy. Addition of...

  • Strategies for Managing Anemia in Hepatitis C Patients Undergoing Antiviral Therapy. McHutchison, John G.; Manns, Michael P.; Brown, Robert S.; Reddy, K. Rajender; Shiffman, Mitchell L.; Wong, John B. // American Journal of Gastroenterology;Apr2007, Vol. 102 Issue 4, p880 

    Anemia is a common side effect that begins soon after the initiation of peginterferon/ribavirin in the treatment of hepatitis C virus (HCV) infection. It can cause symptoms that negatively impact quality of life (QOL) and is the most common reason for reducing the dose and temporarily or...

  • The effect of uremic toxins on the production and metabolism of erythropoietin. Erslev, Allan J. // Kidney International Supplement;Jan1975, Issue 2, pS-129 

    This article presents information on the effects of uremic toxins on the production and metabolism of erythropoietin. Chronic uremia is almost invariably associated with anemia. This association was first noticed by researcher Richard Bright 150 year ago, and for many years, the anemia was...

  • Early decline of hemoglobin correlates with progression of ribavirin-induced hemolytic anemia during interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Oze, Tsugiko; Hiramatsu, Naoki; Kurashige, Nao; Tsuda, Natsuko; Yakushijin, Takayuki; Kanto, Tatsuya; Takehara, Tetsuo; Kasahara, Akinori; Kato, Michio; Yoshihara, Harumasa; Katayama, Kazuhiro; Kubota, Shinji; Hijioka, Taizo; Ishibashi, Kazunobu; Oshita, Masahide; Hagiwara, Hideki; Haruna, Yoshimichi; Mita, Eiji; Tamura, Shinji; Hayashi, Norio // Journal of Gastroenterology;Sep2006, Vol. 41 Issue 9, p862 

    The aim of this study was to examine the factors correlated with the progression of ribavirin-induced hemolytic anemia in patients with chronic hepatitis C treated by interferon and ribavirin combination therapy. This study was conducted on 505 patients by the Osaka Liver Disease Study Group. A...

  • Impact of Inosine Triphosphatase Gene Variants on the Risk of Anemia in HIV/Hepatitis C Virus-Coinfected Patients Treated for Chronic Hepatitis C. Rallón, Norma I.; Morello, Judit; Labarga, Pablo; Benito, José M.; Rodríguez-Nóvoa, Sonia; Vispo, Eugenia; Barreiro, Pablo; Castro, M.Á ngeles; Aguirrebengoa, Koldo; Pineda, Juan A.; Miralles, P.; Tellez, M. Jesús; Portu, Joaquín; Miralles, Celia; Ocampo, Antonio; Soriano, Vincent // Clinical Infectious Diseases;12/15/2011, Vol. 53 Issue 12, p1291 

    The article reports on the role of rs1127354/rs7270101 alleles at the inosine triphosphatase gene on ribavirin-induced anemia. This clinical condition has been assessed in 74 patients with hepatitis C virus and human immunodeficiency virus coinfection. It states that anemia developed in 80...

  • THE BOYZ DOC. WATERS, LAURA // BOYZ;8/6/2015, Issue 1248, p44 

    The article provides an answer to a question on having hepatitis vaccine and prevention of hepatitis C.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics